Status:
RECRUITING
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
Centre Hospitalier de Perigueux
Advanz Pharma
Conditions:
Catheter Bacteremia
Staphylococcus Aureus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary objective of the study is to demonstrate, among patients with non-complicated CR-BSIs due to S. aureus, that a single-dose of intravenous (IV) dalbavancin 1500 mg is non-inferior to standa...
Detailed Description
Catheter-related bloodstream infections (CR-BSIs) are the most common nosocomial bloodstream infections, with an incidence as high as 8.5 to 19.8 infections per 1000 catheter-days. Staphylococcus aure...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
June 23 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 23 2026
Estimated Enrollment :
406 Patients enrolled
Trial Details
Trial ID
NCT05117398
Start Date
June 23 2023
End Date
September 23 2026
Last Update
April 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Infectious Diseases Department, Raymond-Poincaré Hospital - APHP
Garches, France, 92380
2
Infectious Diseases Department, CH PERIGUEUX
Périgueux, France, 24019